- Home
- ELVN vs GAM Comparison
ELVN vs GAM Comparison
Compare ELVN & GAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- GAM
- Stock Information
- Founded
- ELVN 2016
- GAM 1927
- Country
- ELVN United States
- GAM United States
- Employees
- ELVN N/A
- GAM N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- GAM Investment Managers
- Sector
- ELVN Health Care
- GAM Finance
- Exchange
- ELVN Nasdaq
- GAM Nasdaq
- Market Cap
- ELVN 1.1B
- GAM 1.2B
- IPO Year
- ELVN 2020
- GAM N/A
- Fundamental
- Price
- ELVN $22.47
- GAM $51.89
- Analyst Decision
- ELVN Strong Buy
- GAM
- Analyst Count
- ELVN 5
- GAM 0
- Target Price
- ELVN $37.80
- GAM N/A
- AVG Volume (30 Days)
- ELVN 204.7K
- GAM 20.1K
- Earning Date
- ELVN 11-13-2024
- GAM 01-01-0001
- Dividend Yield
- ELVN N/A
- GAM 5.74%
- EPS Growth
- ELVN N/A
- GAM N/A
- EPS
- ELVN N/A
- GAM 11.67
- Revenue
- ELVN N/A
- GAM N/A
- Revenue This Year
- ELVN N/A
- GAM N/A
- Revenue Next Year
- ELVN N/A
- GAM N/A
- P/E Ratio
- ELVN N/A
- GAM $3.95
- Revenue Growth
- ELVN N/A
- GAM N/A
- 52 Week Low
- ELVN $10.90
- GAM $37.32
- 52 Week High
- ELVN $30.03
- GAM $46.48
- Technical
- Relative Strength Index (RSI)
- ELVN 39.53
- GAM 49.44
- Support Level
- ELVN $21.84
- GAM $50.17
- Resistance Level
- ELVN $24.42
- GAM $52.95
- Average True Range (ATR)
- ELVN 1.59
- GAM 0.84
- MACD
- ELVN -0.05
- GAM 0.03
- Stochastic Oscillator
- ELVN 18.27
- GAM 61.69
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About GAM General American Investors Inc.
General American Investors Company Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.